Valuation: MacroGenics, Inc.

Market Cap 15Cr 13Cr 12Cr 11Cr 21Cr 1.39TCr 21Cr 143.72Cr 58Cr 736.02Cr 55Cr 54Cr 2.33TCr P/E 2026 *
-1.48x
P/E 2027 * -1.41x
Enterprise Value 15Cr 13Cr 12Cr 11Cr 21Cr 1.39TCr 21Cr 143.72Cr 58Cr 736.02Cr 55Cr 54Cr 2.33TCr EV / Sales 2026 *
1.36x
EV / Sales 2027 * 1.62x
Free-Float
96.51%
Yield 2026 *
-
Yield 2027 * -
1 day-0.86%
1 week-6.48%
Current month-3.75%
1 month-35.47%
3 months-40.77%
6 months-27.81%
Current year+43.48%
1 week 2.23
Extreme 2.23
2.54
1 month 1.93
Extreme 1.93
3.79
Current year 1.58
Extreme 1.58
5.08
1 year 1.29
Extreme 1.29
5.08
3 years 0.99
Extreme 0.98965
21.88
5 years 0.99
Extreme 0.98965
22.18
10 years 0.99
Extreme 0.98965
36.48
Manager TitleAgeSince
Chief Executive Officer 53 13/08/2025
Director of Finance/CFO 59 01/05/2008
Chief Tech/Sci/R&D Officer 61 -
Director TitleAgeSince
Director/Board Member 73 01/09/2001
Director/Board Member 53 13/08/2025
Director/Board Member 62 01/10/2004
Date Insider Type Main position Quantity % Market Cap. Importance
06/10/26 Exercice

Chief Technology Officer

16,000 0.0251%
19/08/26 Sell

General Counsel

-31,105 0.0489%
17/08/26 Exercice

Chief Technology Officer

80,000 0.1259%
Change 5-day change 1-year change 3-year change Capi.($)
-0.86%-6.48%+59.31%-56.50% 15Cr
+10.00%+4.50%+58.63%+71.20% 6.69TCr
+1.24%+4.49%+24.37%+102.05% 5.65TCr
+1.50%+2.83%+14.35%+79.13% 5.72TCr
+0.46%-5.47%+25.04%+33.77% 4.35TCr
+2.82%+5.82%+240.96%+801.17% 4.28TCr
+6.42%+1.18%+22.18%+105.56% 4.3TCr
+3.33%-2.59%+100.65%+84.32% 3.21TCr
+5.32%+5.37%+19.12%+52.98% 3.4TCr
+5.32%+13.43%-39.82%+342.66% 2.41TCr
Average +4.07%+1.81%+52.48%+161.63% 4TCr
Weighted average by Cap. +4.69%+2.58%+53.48%+170.20%

Financials

2026 *2027 *
Net sales 11Cr 9.64Cr 8.84Cr 8.04Cr 15Cr 1.02TCr 15Cr 105.68Cr 42Cr 541.18Cr 41Cr 40Cr 1.71TCr 9.06Cr 8.07Cr 7.4Cr 6.73Cr 13Cr 856.28Cr 13Cr 88Cr 35Cr 453.21Cr 34Cr 33Cr 1.44TCr
Net income -8.87Cr -7.9Cr -7.25Cr -6.59Cr -12Cr -838.27Cr -13Cr -87Cr -35Cr -443.67Cr -33Cr -33Cr -1.41TCr -14Cr -12Cr -11Cr -10Cr -19Cr -1.3TCr -20Cr -134.86Cr -54Cr -690.66Cr -52Cr -51Cr -2.19TCr
Net Debt - -
Projected Income Statement - Annual - MacroGenics, Inc.
Logo MacroGenics, Inc.
MacroGenics, Inc. is a biopharmaceutical company. The Company is focused on developing antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates from its proprietary suite of antibody technology platforms. It is developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which are referred to as DART and TRIDENT molecules). It has multiple proprietary product candidates. These include three clinical-stage ADCs incorporating a novel topoisomerase I inhibitor (TOP1i)-based linker-payload: MGC026, which targets B7-H3; MGC028, which targets ADAM9, and MGC030, which is directed against an undisclosed target. It is also developing lorigerlimab, a clinical-stage bispecific DART molecule targeting the immune checkpoint receptors PD-1 and CTLA-4. In addition, it is also developing multiple preclinical-stage ADC and next-generation T-cell engager programs.
Employees
293
Date Price Change Volume
04/26/04 $2.310 -0.86% 9,19,162
03/26/03 $2.330 0.00% 4,09,139
02/26/02 $2.330 -2.92% 7,66,121
30/26/30 $2.400 +0.84% 11,82,982
29/26/29 $2.380 -3.64% 7,44,479
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - MacroGenics, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
2.310USD
Average target price
8.000USD
Spread / Average Target
+246.32%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - MacroGenics, Inc.
  1. Stock Market
  2. Stocks
  3. MGNX Stock